Article Per Year (5 Year)
p-Index From 2021 - 2026
0
P-Index
This Author published in this journals
All Journal Cermin Dunia Kedokteran
Tumewu, Aaron
Unknown Affiliation
Health Professions Medicine & Pharmacology Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Kontroversi Penggunaan Amiodaron untuk Terapi Atrial Fibrillation pada Penderita Sindrom Wolff-Parkinson-White Tumewu, Aaron
Cermin Dunia Kedokteran Vol 45, No 8 (2018): Alopesia
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (189.08 KB) | DOI: 10.55175/cdk.v45i8.636

Abstract

Sindrom Wolff-Parkinson-White (WPW) dikombinasi dengan atrial fibrillation (AF) merupakan kondisi yang mengancam nyawa sehingga dibutuhkan terapi segera. Amiodaron, yang berdasarkan klasifikasi Vaughan-Williams merupakan agen antiaritmia kelas III, memiliki mekanisme kerja mencakup seluruh kelas antiaritmia dan paling sering digunakan dalam terapi terminasi AF. Akan tetapi pada kondisi sindrom WPW dengan AF, amiodaron dapat memperburuk aritmia hingga menjadi ventricular fibrillation (VF) akibat efek kerjanya yang dapat menghambat konduksi di nodus atrioventrikular (AV).Wolff-Parkinson-White (WPW) Syndrome combined with atrial fibrillation (AF) is a life-threatening condition that needs immediate treatment. Amiodarone, according to Vaughan-Williams classification, is a class III antiarrhythmic with activities of all four antiarrhythmic classes; it is the most common drug used for AF termination. But in AF with WPW syndrome, amiodarone may aggravate the condition into ventricular fibrillation (VF) due to its effect on inhibiting atrioventricular (AV) node conduction.
Co-Authors